Clinical Trials Browser

Phase 3 × Completed × tislelizumab × Clear all

NCT03412773 2025-10-14

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Phase 3 Completed

684 enrolled 43 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03957590 2025-05-02

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04005716 2025-02-28

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3 Completed

457 enrolled 20 charts

Small Cell Lung Carcinoma

NCT03358875 2025-02-10

RATIONALE-303

Phase 3 Completed

805 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT03663205 2025-02-04

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

334 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

512 enrolled 27 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis